Research programme: calcium channel modulators - Pascal Biosciences

Drug Profile

Research programme: calcium channel modulators - Pascal Biosciences

Latest Information Update: 03 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioMmune Technologies; University of British Columbia
  • Developer Pascal Biosciences; University of British Columbia
  • Class
  • Mechanism of Action Calcium channel modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders; Cancer; Infections

Most Recent Events

  • 30 Mar 2017 ​BioMmune Technologies is now called Pascal Biosciences
  • 29 Jun 2016 BioMmune Technologies has patent protection for monoclonal antibodies that modulate voltage gated calcium channels in China
  • 03 Mar 2014 Early research in Autoimmune disorders in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top